CytomX Therapeutics, Inc. / Estimates

    Fiscal Year Revenue Net income Net margin Free cash flow FCF margin
    (estimated) €117.75M +269.6% €6.88M -113.6% 5.8% +1.6 pp N/A N/A
    (estimated) €31.86M -28.9% -€50.55M +13.9% -158.7% -0.60 pp N/A N/A
    (estimated) €44.82M +4.9% -€44.40M +15.7% -99.1% -0.092 pp €5.70M -362.7% 12.7% +0.18 pp
    (estimated) €42.71M -46.7% -€38.36M -794.7% -89.8% -0.97 pp -€2.17M -92.3% -5.1% +0.30 pp
    (estimated) €80.08M -32.7% €5.52M -79.9% 6.9% -0.16 pp -€28.25M -61.8% -35.3% +0.27 pp
    €118.98M +36.4% €27.46M -5,700.9% 23.1% +0.24 pp -€74.03M +55.7% -62.2% -0.077 pp
    €87.20M +90.4% -€490.22K -99.4% -0.6% +1.8 pp -€47.55M -49.4% -54.5% +1.5 pp
    €45.80M -23.6% -€83.83M +20.6% -183.0% -0.67 pp -€93.95M -7.1% -205.1% -0.36 pp
    €59.94M -30.7% -€69.48M +145.2% -115.9% -0.83 pp -€101.16M -1,651.6% -168.8% -1.8 pp
    €86.47M +74.6% -€28.33M -67.8% -32.8% +1.5 pp €6.52M -105.5% 7.5% +2.5 pp
    €49.53M -3.4% -€88.08M +20.8% -177.8% -0.36 pp -€118.02M +91.0% -238.3% -1.2 pp
    €51.26M -16.9% -€72.89M +96.3% -142.2% -0.82 pp -€61.80M -141.7% -120.6% -3.6 pp
    €61.71M +376.1% -€37.13M -26.8% -60.2% +3.3 pp €148.13M +119,297.2% 240.1% +2.4 pp
    €12.96M +95.1% -€50.75M +66.5% -391.5% +0.67 pp €124.06K -100.6% 1.0% +3.4 pp
    €6.64M +51.9% -€30.48M +16.7% -458.7% +1.4 pp -€22.25M -177.2% -334.8% -9.9 pp
    €4.37M +471.7% -€26.11M +100.2% -597.0% +11 pp €28.83M -559.9% 659.1% +15 pp
    €765.06K -€13.05M -1,705.3% -€6.27M -819.4%

    Notifications